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Abstract
In this paper, we develop an analytical framework for personalizing the anticoagulation
therapy of patients who are taking warfarin. Consistent with medical practice, our treatment
design consists of two stages: (i) the initiation stage, modelled using a partially-observable
Markov decision process, during which the physician learns through systematic belief updates
about the unobservable patient sensitivity to warfarin, and (ii) the maintenance stage, mod-
elled using a Markov decision process, during which the physician relies on his formed belief
about patient sensitivity to determine the stable, patient-specific, warfarin dose to prescribe.
We develop an expression for belief updates in the POMDP, establish the optimality of the
myopic policy for the MDP, and derive conditions for the existence and uniqueness of a my-
opically optimal dose. We validate our models using a real-life patient data set gathered at
the Hematology Clinic of the Jewish General Hospital in Montreal. The proposed analytical
framework and case study enable us to develop useful clinical insights, e.g., concerning the
length of the initiation period and the importance of correctly assessing patient sensitivity.
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1. Introduction
The field of medicine has spent a considerable effort on the standardization of care during
the past few decades. However, recognizing the drawbacks of this “one size fits all” approach,
the more recent trend has been the development of personalized treatment schemes which
incorporate patient-specific characteristics and are tailored to each patient’s personal needs;
e.g., see Hamburg and Collins (2010) and Personalized Medicine Coalition (2015).
In this paper, we focus on anticoagulation therapy for stroke prevention in atrial fib-
rillation (AF), and present an analytical framework for its personalization. In so doing,
we are motivated by recent clinical evidence presented by the American Heart Association
(2014) who stated that “most management strategies for (anticoagulation therapy) should
be individualized,” that “more research is needed for individualized approaches”, and that
determining “the optimal treatment (...) remains challenging”.
Atrial Fibrillation and Warfarin. Warfarin is the most commonly prescribed antico-
agulant drug in the world. However, despite warfarin’s popularity, its usage is complicated
by a narrow therapeutic window. Indeed, a high warfarin dose could have life-threatening
consequences, such as excessive bleeding, while a low warfarin dose could be ineffective in
preventing the formation of blood clots which, in turn, increases the risk of stroke; see Old-
gren et al. (2011). Moreover, patient response to warfarin is affected by both demographic
and clinical factors (age, ethnicity, gender, and diet), and is strongly influenced by several
comorbid conditions. Warfarin is also known to interact with other medication that the
patient may be taking; e.g., see White et al. (2010). Due to those complications, warfarin
remains designated as one of the most unsafe drugs; see the Institute for Safe Medication
Practices (2012) and the American Stroke Association (2015).
Recent medical research indicates that pharmacogenetic factors, i.e., genetic differences
between patients, may significantly affect patient response to warfarin; see Botton et al.
(2011). Nevertheless, genetic testing remains difficult, costly, and not widely used; e.g.,
see Patrick et al. (2009), Ginsburg and Voora (2010), and Bhatt (2014). This evidence has
prompted Holbrook et al. (2012) to specify in the 2012 ACCP guidelines that genetic testing
is “ not (considered) cost effective by most drug policy experts.” (p. e159S). Therefore, there
is a need for a treatment design that enables systematic learning about that unobservable
patient sensitivity without expensive genetic testing. In this paper, we propose such a design.
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Personalized Treatment Design for AF. Physicians typically use the International
Normalized Ratio (INR) to quantify patient response to warfarin. The desired INR range
for patients with AF is between 2 and 3. There are two stages involved (International
Warfarin Pharmacognetics Consortium, 2009). In the initiation stage, the physician learns
about patient sensitivity so as to prescribe an appropriate warfarin dose. In the maintenance
stage, the physician assumes prior knowledge of his patient’s sensitivity, with some acceptable
degree of uncertainty, and prescribes a stable warfarin dose accordingly. In this paper, we
model both stages involved in anticoagulation therapy. In particular, we use a partially-
observable Markov decision process (POMDP) to model the initiation stage of treatment and
enable learning about the unobservable patient sensitivity, and a Markov decision process
(MDP) to model the maintenance stage of treatment. As such, ours is the first paper which
proposes a systematic approach for the entire treatment process.
Contributions. We develop a closed-form expression for belief updates (about sensitivity)
in the POMDP framework; we prove that the myopic policy is optimal for the MDP model;
and we formulate sufficient conditions for the existence and uniqueness of the myopically
optimal warfarin dose for the MDP model: This is the stable dose; see Botton et al. (2011).
We also analyze the impact of this risk-minimizing dose on the time in therapeutic range
(TTR). The TTR is defined as the proportion of visits that the INR remains within the
target interval (2, 3) (Ansell et al., 2001). We prove that, contrary to common medical
belief, a risk-minimizing dose may not always lead to a desirable TTR.
Our work is grounded in the realities of current medical practice. The real-life patient
data, which we use in calibrating the proposed methodology, are gathered at the Hematology
Clinic of the Jewish General Hospital in the city of Montreal, Canada. We show that our
proposed models fit the data well. Last but not least, we conduct a detailed numerical study
and show, numerically, that the myopic policy is very close to optimal for the POMDP
model. This suggests that it suffices for physicians to solve the single-stage belief updating
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problem, at each decision epoch, during the initiation stage. We also formulate several
recommendations, e.g., concerning the required length of the initiation period and how it is
affected by the level of patient sensitivity, the effect of previous adverse events on subsequent
treatment, and the importance of correctly assessing patient sensitivity.
Literature Review. In this paper, we contribute to the emerging body of literature em-
ploying operational research techniques for the personalization of medical guidelines, which
was designated as one of the main open research challenges in Denton et al. (2011). In a set-
ting such as ours, where medical decisions need to be made sequentially in highly stochastic
environments, Markov decision processes (MDP) are ideally suited; see Shaefer et al. (2004)
for a comprehensive survey. More recent references include MDP applications to liver trans-
plantation (Alagoz et al., 2007), to HIV (Schechter et al., 2008), ovarian hyperstimulation
(He et al., 2010), the timing of biopsy decisions in mammography screening (Chhatwal et
al. 2010), and the optimizing of diagnostic decisions after a mammography (Avyaci et al.,
2012). POMDPs are an extension of MDPs which relax the assumption that the state of
the system is known. Recent references include POMDP applications to to heart disease
(Hauskrecht and Fraser, 2000), Parkinson’s disease (Goulionis and Vozikis, 2009), colorectal
cancer (Leshno et al. 2003), breast cancer (Maillart et al., 2008 and Ayer et al., 2010), and
stroke (Coroian and Hauser, 2015). The work of Coroian and Hauser is different from ours
in that the authors do not solve the problem of determining personalized dosing decisions, as
we do in this paper. Instead, they focus on selecting the learning technique in the POMDP
framework which optimizes predictive accuracy. Witt et al. (2009), Klein et al. (2009),
Millican et al. (2007), Botton et al. (2011), and references therein, use regression models to
determine the stable warfarin dose as a function of several covariates. However, they do not
address how to sequentially learn about an unobservable patient sensitivity.
The remainder of this paper is organized as follows. In §2, we describe our two-stage
framework. In §3, we describe our POMDP model, and in §4, our MDP model. In §5,
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Initiation stage 
 Patient visit:
0. Measure patient INR
1. Update belief about γ
2. Prescribe new warfarin dose
Steps 0−2 are repeated until a desired
level of confidence about γ is reached
Maintenance stage 
           Stable warfarin dose 
Figure 1: Conceptual framework.
we describe our data set. In §6, we fit our POMDP model to data. In §7, we describe
our detailed numerical study. In §8, we make concluding remarks. We include supportive
material in an online supplement to this paper.
2. General Framework: A Two-Stage Methodology
In Figure 1, we describe the conceptual framework of this paper. We use a POMDP frame-
work to model the initiation stage of treatment. At the onset of treatment, the physician
has some initial belief about the patient’s sensitivity. At each patient visit to the clinic, the
physician measures the patient’s INR. Based on this new INR measurement and the patient’s
treatment history, the physician updates his/her belief about the patient’s sensitivity. Based
on this updated belief, the physician aims to prescribe an optimal, risk-minimizing, warfarin
dose. We quantify the risk associated with a given INR value by using a convex combination
of bleeding and stroke relative risks. For the functional forms of the bleeding and stroke
risks, we rely on the literature; see Hylek et al. (2003).
The belief-updating steps are repeated until the physician forms a belief about the pa-
tient’s sensitivity which is deemed to be sufficiently accurate. We assume that the conver-
gence criterion for the POMDP (the level of desired accuracy about the patient’s sensitivity)
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is exogenously specified. We do so intentionally because of the inherent tradeoff between the
clinical benefits of enhanced learning about patient sensitivity on one hand, and the incon-
venience of frequent visits to the clinic during the initiation stage on the other hand. Indeed,
clinical visits are typically costly for patients; e.g., see Hwang et al. (2012) and Shariff et al.
(2012). Since we take the physician’s perspective in this work, we do not consider additional
costs incurred by the patient per visit to the anticoagulation clinic. However, we indirectly
allow for those costs by assuming an exogenous stopping criterion for the POMDP.
We use an MDP framework to model the maintenance stage of treatment. Based on a
preformed belief about the patient’s sensitivity, which results from the initiation stage, the
physician prescribes the optimal dosage. We prove that the myopic policy is optimal for that
MDP, so that it suffices to solve the single-stage problem at each decision epoch.
In this paper, we determine optimal dosing decisions in the initiation and maintenance
stages separately. An alternative approach is to jointly solve the problems in both stages. In
a joint solution, the physician makes optimal dosing decisions which minimize the total ex-
pected discounted risk, cumulative over both stages, up to and beyond the stopping criterion
(for belief updating) in the initiation stage. We opt against such a joint solution approach
for two main reasons. First, our two-stage solution is in line with the realities of medical
practice where initiation and maintenance are typically treated independently because they
involve different visit frequencies, risks, and clinical objectives. Second, commercially avail-
able software for solving POMDP’s does not allow for such a joint solution where there is
no belief updating beyond a certain, pre-specified, point (end of initiation stage).
In general, a joint solution should typically lead to a smaller cumulative expected risk
compared to a separate solution. In the supplement, we numerically compare between the
joint and separate solutions of the problem, and show that they do not differ greatly; as
such, our two-stage solution approach is further justified.
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3. The Initiation Stage of Treatment
We formulate a discrete-time, finite-horizon, POMDP model to solve the initiation-stage
problem. In this modelling framework, a single decision maker (the physician) minimizes
the cumulative expected risk for the patient by prescribing appropriate warfarin dosages at
successive decision epochs, i.e., at clinical visits. A POMDP model is appropriate because
the physician cannot directly observe patient sensitivity to warfarin, i.e., the states of the
process are partially hidden. In this section, we first present the POMDP model, then we
describe both our dose-response model and the belief updating procedure.
3.1. POMDP Model Formulation
In order to behave optimally in a partially observable setting such as ours, it is necessary to
use the history of the treatment to aid in the disambiguation of patient sensitivity. Based on
previous dose prescriptions and corresponding INR measurements, the physician maintains
and updates a probability distribution over the set of possible patient sensitivity values.
This probability distribution represents the physician’s current belief about patient sensi-
tivity. Consecutive optimal dosages depend on sequentially updated beliefs. Our POMDP
framework constitutes a systematic way of doing that. Here is some notation that we use.
Decision Epochs: t = 1, 2, ..., T . Each decision epoch in the POMDP model corresponds
to a patient visit to the clinic, i.e., t = i corresponds to the ith visit, where 1 ≤ i ≤ T .
Consistent with medical practice, we assume that the times between successive visits are
long enough to allow for doses to exert their full effects; e.g., visits are scheduled every 2 or
3 days. We make no other assumptions about the times between successive decision epochs.
The time horizon, T , taken to be the time needed to adequately learn about patient
sensitivity, is typically not known at the onset of treatment. Indeed, T depends both on the
desired ensuing level of confidence about patient sensitivity and the specific characteristics
of the patient at hand. In §7, we use simulation to estimate the number of visits required to
7
form different confidence levels (about sensitivity) for alternative patients.
State Space: S. We let st ∈ S denote the state of the system at time t. In particular,
we let st be the pair (INRt, γt), where INRt is the INR of the patient at t, and γt is the
sensitivity of the patient at t. We assume that the physician measures INRt but cannot
observe γt. Instead, the physician must maintain and update a belief distribution about γt.
We let γt be the slope of a linearly additive Gaussian dose-response model for the natural
logarithm of INRt; see §3.2. In our model, we do not impose a finite state space. Instead, we
assume that both INRt and γt may take values in the set of nonnegative real numbers. We
take patient sensitivity to be the result of the patient’s genetic information which does not
vary with time. Thus, in our context, it is reasonable to make the assumption of a constant,
time-invariant, γt; accordingly, we drop the time subscript, t, from its notation.
Action Space: A. We let dt ∈ A be the warfarin dose (in milligrams) prescribed by the
physician at visiting epoch t. That is, dt ≥ 0.
POMDPs are computationally difficult to solve; see Braziunas (2003). Indeed, since the
underlying states are not known with certainty, the decision maker has to base his decisions
on belief states. Since a belief state assigns a given probability to every system state, there
is a continuous number of possible belief states to encounter. Essentially, solving a POMDP
amounts to solving a continuous state-space belief MDP; e.g., see Hauskert and Fraser (2000).
To alleviate some of that computational burden, and to be consistent with medical prac-
tice, we discretize the action and state spaces, A and S, when numerically solving our
POMDP in §7. For simplicity, and to be consistent with our subsequent numerical results,
we hereafter use notation which is consistent with having a discrete state space.
State-Transition Function: PS : S × A × S → [0, 1]. We let PS(s, d, s′) denote the
probability that the next state is s′ given that the current state is s and the current action
taken is d. This probability is specified by our dose-response model; see §3.2. (We assume
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time-homogeneous transition probabilities.) In a model with time-independent γ, we assume
that transitions from a given state (INRt, γ) to other states with different γ values are not
possible, i.e., PS((INR, γ), d, (INR
′, γ′)) = 0 if γ 6= γ′. In §6 and §7, we discretize states by
replacing individual INR values by corresponding intervals.
Observation Space: O. We denote an observation made at time t by ot ∈ O. Since we
assume that the physician can only observe INRt at t, we let ot = INRt.
Observation Probability Function: PO : S × O → [0, 1]. We let PO(s, o) denote the
probability of making observation o given that the current state is s. In our context, PO
has the following simplified form. Since we assume that the physician correctly measures
the patient’s INR at each visiting epoch, we must have that PO((INR, γ), INR
′) = 1 if and
only if INR = INR′ and PO((INR, γ), INR′) = 0 otherwise. Allowing for measurement errors
in the INR, or for INR measurements outside scheduled clinical visits, e.g., as would be the
case with patient self-monitoring of their INR, are left as directions for future research.
Belief space: B. An element b ∈ B is a probability vector over possible γ values. (To
denote the belief at a particular state s, we will use the notation b(s).) The policy component
of a POMDP maps the physician’s current belief state into an optimal dose. In §3.3, we
describe how the physician transitions between different belief states.
Risk function: r : S × A → R, where R denotes the set of real numbers. This function
gives the immediate risk, r(s, d), associated with prescribing a dose d and ending up in state
s; for a specification of this risk function in our case study, see §5.
Our objective is to minimize the cumulative discounted expected risk over the horizon T .
The solution of the POMDP can be carried out using dynamic programming techniques; see
Bellman (1957). Let the value function V ∗j denote the optimal expected reward when there
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are j steps to go until T . Then, V ∗j satisfies the following Bellman’s equation:
V ∗j+1(b) = min
d∈A
{
R(b, d) + θ
∑
o∈O
p(b, d, o)V ∗j (τ(b, d, o))
}
, (3.1)
where θ is some discount factor (since the decision does not observe the underlying state,
we do not sum over these). In (3.1), p(b, d, o) is the probability of making an observation o
in the next epoch given that the current action is d and the current belief is b, and R(b, d)
is the expected one-step risk given current belief b and action d. That is, p(b, d, o) can be
calculated using basic probability as follows:
p(b, d, o) =
∑
s′∈S
PO(s
′, o)PS(s, d, s′)b(s).
In (3.1), τ is an update function that computes a new belief b′ = τ(b, d, o) given the current
belief b, the current dose decision d, and the future observation o; see §3.3. Finally, in (3.1),
R(b, d) can be calculated as:
R(b, d) =
∑
s′∈S
∑
s∈S
r(s′, d)PS(s, d, s′)b(s).
It was shown in Smallwood and Sondik (1973) that the value functions for POMDPs are
finite, piecewise linear, and convex which greatly simplifies the solution of (3.1). We will
make use of that piecewise linear representation when solving our POMDP in §7.
3.2. Dose-Response Model
We model the log-transformed INR using a linearly additive Gaussian model with several
clinical and demographic fixed effects. In §5, we fit this model to data.
Let tj1 < t
j
2 < ... < t
j
Nj
be the visiting epochs for patient j. Let N j be the total number
of visits for patient j. Let INRji be the INR of patient j measured at visiting epoch t
j
i .
Define Y ji ≡ ln(INRj) where ln(·) denotes the natural logarithm function. Let dji be the dose
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prescription between tji−1 and t
j
i , resulting in INR
j
i . Let γ
j denote the sensitivity of patient
j. Our model for the log-transformed INR is given by:
Y ji ≡ ln(INRji ) =
K∑
k=1
νkI
j
k + γ
jdji + 
j
i = β + γ
jdji + 
j
i , (3.2)
where β is defined as β ≡ ∑Kk=1 νkIjk and 1 ≤ i ≤ N j. We let ji be independent and
identically distributed (i.i.d.) normal random variables with mean 0 and variance σ2 . We let
Ijk be an indicator random variable which equals 1 when fixed effect k is present for patient
j. We define K as the total number of fixed effects. For example, if k corresponds to gender,
then we let Ijk = 1 when patient j is male, and 0 otherwise. We omit the superscript j when
the specific patient index does not matter. In Table 1 of the supplement, we describe all
fixed effects in (3.2). The parameters νk in (3.2) and the variance parameter, σ
2
 , need to be
estimated from data. In §6, we use (3.2) to compute state transition probabilities.
3.3. Belief Updates
The physician is uncertain about the value of γ, which he treats as random. Here, we
assume that the physician’s initial belief about γ is normally distributed with mean µ0 and
variance σ20. In Bayesian parlance, this is the prior distribution. (We selected a normal prior
for analytical convenience; however, we conducted numerical experiments using a lognormal
prior instead and reached largely the same conclusions.) Let Y1, Y2, ..., Yn denote the history
of log-transformed INR observations up to, and including, epoch n, and the parameters β,
di for 1 ≤ i ≤ n, and σ2 be defined as in (3.2). Then, the following lemma holds.
Lemma 3.1. The updated belief distribution about γ at the nth decision epoch is normal
with variance σ2n =
(
1
σ20
+
∑n
i=1
d2i
σ2
)−1
and mean µn = σ
2
n
(∑n
i=1 di
yi−β
σ2
+ µ0
σ20
)
,
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Proof. The proof readily follows from conditional multivariate Gaussian theory and the
linearity assumption in (3.2). Indeed, we can write the following vector equation:
(Y1, ..., Yn) = (d1, d2, ..., dn) · γ + (β, β, ..., β) + (1, ..., n),
where γ is normally distributed with mean µ0 and variance σ
2
0, . The updated belief dis-
tribution about γ is the conditional distribution of γ given the observations Y1 = y1, Y2 =
y2, ..., Yn = yn. This conditional distribution can be easily shown to be normal as well; ap-
plying equations (2.113)-(2.117) of Bishop (2006) yields the desired expressions for the mean
and variance of this conditional distribution, as stated in the lemma.
It is insightful that the variance term in Lemma 3.1 decreases with increasing dosages.
This indicates that, at any decision epoch prior to T , a myopically suboptimal dose may
be optimal for the POMDP since it may lead to faster learning about γ (reduction in the
belief distribution’s variance). In other words, the optimal solution for the POMDP bal-
ances, at every epoch, risk minimization with faster learning about γ. This is known as the
“exploitation versus exploration” tradeoff in reinforcement learning.
4. The Maintenance Stage of Treatment
In the maintenance stage, the physician assumes prior knowledge of his patient’s sensitivity,
with some degree of uncertainty, and prescribes warfarin doses accordingly. We model the
maintenance stage of treatment using a discrete-time, finite-horizon MDP framework. We
begin by briefly describing our MDP model, and then derive some relevant analytical results.
4.1. MDP Model Formulation
State Space and decision epochs. We define the state of the MDP, at a given decision
epoch, to be the observable INR. As such, the state of the process is fully observable which
makes the MDP framework appropriate. The decision epochs correspond, as in the POMDP
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framework, to patient visiting epochs to the clinic.
State transition function. Transitions between system states are specified by the dose-
response model in (3.2) where, taking the physician’s perspective, γ is now assumed to be
normally distributed with a mean of µM and a variance of σ
2
M . That is, the log-transformed
INR is assumed to be normally distributed with a mean equal to β + diµM and a variance
equal to d2iσ
2
M +σ
2
 . The distribution of γ at the onset of the maintenance stage results from
belief updates during the initiation stage: µM and σ
2
M are given by Lemma 3.1, and depend on
the entire history of treatment during the initiation stage. We assume that the distribution
of γ does not change during the maintenance stage, i.e., consistently with medical practice,
the physician’s belief about patient sensitivity is invariant during that stage.
Action space, risk function, horizon, and objective. The action space and risk func-
tion for the MDP are as in §3.1. The time horizon, TM is set to 100 visits. Finally, the
objective of the problem remains to determine appropriate dosages so as to minimize the
total expected cumulative risk. Let H∗j denote the optimal expected reward when there are
j steps to go until TM . Then, H
∗
j satisfies the following Bellman’s equation:
H∗j+1(s) = min
d∈A
{
r(s, d) + θ
∑
s′∈S
PS(s, d, s
′)H∗j (s
′)
}
. (4.1)
4.2. Optimality of the Myopic Policy
We now characterize the optimal policy for the MDP.
Theorem 4.1. The myopic, single-stage, policy is optimal for the MDP.
Proof. Our proof proceeds by induction on the number, n, of remaining epochs until TM .
It is not hard to see that the induction hypothesis holds initially: n = 0 corresponds to
time TM , at which point it is optimal to select the myopically optimal dose. To prove the
inductive step, we assume that myopically optimal doses are optimal for the MDP for the
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final k decision epochs, i.e., for all n ≤ k, where k ≤ TM is some nonnegative integer. We
now show that the same must hold for n = k+ 1. Let dTM−k be the selected dose when there
are n = k + 1 decision epochs remaining. Since the distribution of γ is invariant during the
maintenance stage, the future dynamics of the system and, in particular, the future risks are
unaffected by dTM−k. Thus, given that future optimal doses are also myopically optimal, by
the induction hypothesis, the same must also hold for dTM−k; indeed, there is no advantage
in selecting a myopically subpotimal dose for dTM−k. This completes the inductive proof.
The myopic, single-stage, problem is the same across all decisions epochs of the MDP.
Thus, the solution to that problem, if it exists and is unique, is constant throughout the
maintenance stage. This coincides with medical practice where it is common that a unique,
stable, dose is prescribed to patients during the maintenance stage of treatment; e.g., see
Witt et al. (2009), Klein et al. (2009), Millican et al. (2007) and Botton et al. (2011). Next,
we investigate sufficient conditions for the existence and uniqueness of that stable dose.
4.3. Stable Dose
Consistent with the literature, we assume that the stroke and bleeding risks are exponential
functions of the INR; see Rosendaal et al. (1993). For exact functional forms, we rely on
previous literature; e.g., see Hylek et al. (2003).
We focus on relative risks of stroke and bleeding, as a function of the reported INR
for the patient. The relative risk for stroke (bleeding) is the ratio between the (estimated)
probability of stroke for a given INR value, and the (estimated) probability of stroke for
a baseline INR value lying in the desired interval (2, 3). Indeed, most current guidelines
recommend an INR target of 2.5 (with the range of 2 and 3); see Oden et al. (2006).
Usually, estimates of probabilities of stroke and bleeding events are reported in the liter-
ature in units of incidence rates per 100 patient-years for a given INR level; e.g., see Hylek
et al. (2003), Hylek et al. (2007), and Patrick et al. (2009). More precisely, a cohort of
patients is followed up for some period of time during warfarin treatment, usually a year,
14
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Figure 2: Weighted total risk function, minimized at an INR of 2.5.
and the proportion of patients during that year who have experienced an adverse event, be
it a stroke or a severe bleeding, for a given INR value, is reported.
It is important to note that relative risks do not have time units, since they are ratios
of probabilities, and that is why we assume that they are independent of time. We let the
total risk associated with a given INR be equal to a convex combination of the corresponding
stroke and bleeding risks. We choose the weights in this convex combination so that the risk
is minimized for an INR value of 2.5. In the appendix (§??), we justify the additive nature
of our risk criterion in solving the POMDP and MDP models.
In Figure 2, we plot the resulting risk function. For analytical tractability, we use an
approximating quadratic function (dashed curve) as our risk function. Figure 2 shows that
this is a good approximation for reasonable values of the INR. In closed form, for a given
INR value equal to x, where x ≥ 0, the risk function r(x) can then be given by
r(x) = a+ b(x− c)2 ; (4.2)
in Figure 2, a = 1.19, b = 2/7, and c = 2.5.
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The single-stage problem, to be solved at every decision epoch i of the MDP, is to
minimize E[r(eYi)] where Yi = β + γdi + i is normally distributed with a of mean β + diµM
and a variance of d2iσ
2
M + σ
2
 . That is, e
Yi is lognormally distributed.
Given the quadratic form of the risk function in (4.2), the myopically optimal dose is the
one which minimizes E[(eYi − c)2], i.e., it minimizes V ar[eYi ] + (E[eYi ] − c)2. Hereafter, we
drop dependence on i since the specific visiting epoch does not matter. By exploiting the
properties of the lognormal distribution, our single-stage problem becomes:
min
d≥0
(eσ
2
Md
2+σ2 − 1)(E[eY ])2 + (E[eY ])2 − 2cE[eY ] + c2,
where we can drop the constant term and simplify as follows:
min
d≥0
eσ
2
Md
2+σ2 (E[eY ])2 − 2cE[eY ]. (4.3)
We can expand (4.3) using the fact that E[eY ] = eβ+µMd+0.5(d
2σ2M+σ
2
 ), and obtain:
min
d≥0
e2β+2µMd+2σ
2
Md
2+2σ2 − 2ceβ+µMd+0.5σ2Md2+0.5σ2 .
In the following theorem, we investigate sufficient conditions guaranteeing the existence and
uniqueness of a stable dose. Essentially, the lower bound in these conditions guarantees that
the objective of our single-stage problem is strictly convex. We impose the upper bound to
guarantee the existence of a local minimum, which must, by strict convexity, be both global
and unique. We relegate the proof of the theorem to the appendix.
Theorem 4.2. A sufficient condition for the existence and uniqueness of the stable dose is
the following:
max{ c
2
,
cσ4M
3σ4M + 4σ
2
Mµ
2
M + µ
4
M
,
cσ2M
σ2M + µ
2
M
} < eβ+1.5σ2 < c,
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where µM and σ
2
M are the physician’s belief about the mean and variance of γ, respectively,
at the beginning of the maintenance stage; β and σ2 are as in (3.2).
4.4. An Alternative Criterion: Time in Therapeutic Range
The time in therapeutic range, TTR, is defined as the probability that the INR lies in the
therapeutic range; see Ansell et al. (2001). The higher the TTR, the more effective the
treatment. In this section, we investigate how the TTR maximization and risk minimization
criteria are different, in the maintenance stage, by computing the optimal dose under each
criterion. This is important because those two criteria are often confused in practice.
In what follows, we assume an idealized scenario where patient sensitivity is known. (For
numerical results comparing the two criteria when there is uncertainty about γ, see Table
S2 in the supplement.) We denote patient sensitivity by γa. Under that assumption, we can
derive a closed-form expression for the optimal dose under each criterion; see Lemma 4.1.
The dynamics of the log-transformed INR are given by Y = β + γad + . The optimal dose
under the TTR criterion maximizes the probability that eY lies in the therapeutic range; the
optimal dose under the risk minimization criterion minimizes E[(eY − c)2].
Lemma 4.1. The stable dose which maximizes the TTR is:
d∗TTR =
ln(2) + ln(3)− 2β
2γa
,
and the stable dose which minimizes the risk is:
d∗R =
1
γa
(ln(c)− β − 1.5σ2 ),
for known patient sensitivity γa, and β and σ
2
 as in (3.2).
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Proof. Given the normality of Y , a closed-form expression for the TTR is given by
TTR = P (Y ∈ (ln(2), ln(3))) = Φ
(
ln(3)− β − γad
σ
)
− Φ
(
ln(2)− β − γad
σ
)
, (4.4)
where Φ(·) is the cumulative distribution function of a normal random variable with a mean
equal to 0 and a variance equal to 1. Given (4.4), we see that selecting d such that the origin
is the midpoint of the interval ((ln(2) − β − γad)/σ, (ln(3) − β − γad)/σ) maximizes the
TTR. This corresponds to an optimal value d∗TTR as in the statement of the lemma.
Deriving the risk minimizing dose amounts to solving the problem
min
d≥0
e2β+2γT d+2σ
2
 − 2ceβ+γT d+0.5σ2 .
Upon differentiation of the objective function and setting the derivative to 0, we obtain that
the unique minimizing dose is d∗R = (ln(c)− β − 1.5σ2 )/γT , as desired.
Interestingly, the optimal dosages under the TTR maximization and risk minimization
criteria can be quite different. For example, for a patient sensitivity equal to the average
sensitivity in our data set, and for β and σ2 as estimated from our data, we find that d
∗
TTR = 4
mgs (leading to a maximal value of the TTR equal to 47.5%) whereas d∗R = 2.34 mgs: such
dosages typically lead to different patient responses in practice. In this section, we compared
the TTR and risk criteria in the maintenance stage of the problem. In §2 of the supplement,
we include numerical results comparing the TTR and risk criteria in the initiation stage (by
solving the POMDP under each criterion), and show that when there is uncertainty about
γ, the difference in performance between those two criteria is generally not too great.
4.5. Adverse Events
The occurrence of a previous stroke is incorporated in the fixed effect term, β, in our dose-
response model. Thus, in the event of a stroke, β should be updated. Consequently, the
future dynamics of the INR and all subsequent risks (which are functions of the INR) are
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effected by that stroke event through the updated value of β. In §7, we include a numerical
study which quantifies the effect of ignoring a previous stroke on future dosages.
5. The Case Study
The data were gathered at the hematology clinic of the Jewish General Hospital in Montreal,
Canada. They were collected over several years, ranging from January 3, 2000 to May 10,
2007. The data describe the anticoagulation treatment of 547 patients diagnosed with AF,
and taking warfarin to reduce their risk of stroke. Each patient’s treatment consists of
successive visits to the clinic. At each visit, the patient’s INR is measured through a blood
test and, depending on this INR value, a new warfarin dose (in mgs) is prescribed. In our
data set, warfarin dose prescriptions are based solely on the physician’s best judgment. As
this is the common situation in practice, there is no systematic bias in the data resulting
from the usage of a specific algorithm to determine warfarin dose recommendations.
5.1. Description of the Data Set
Our data set contains both demographic and clinical information for each patient. Demo-
graphic information consists of age and gender. Clinical information can be divided into two
main categories. The first category describes the relevant past medical history of the patient,
i.e., the presence of other diseases. The second category contains information relating to the
bleeding risk of the patient. In Table 1 of the supplement, we specify all data variables.
We do not have any additional information about how patients manage their prescrip-
tions. In the absence of such information, we assume that all doses are consistently taken by
patients, as prescribed, throughout their treatments. The data set represents all patients at
the hematology clinic who are receiving warfarin for stroke prevention, and who were active
patients for given time period. As such, there is no sampling bias, and the data does not
correspond to only one physician. In Figure 3, we plot INR measurements for three patients
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who received treatment at the clinic. Figure 3 illustrates the need to develop a more ef-
fective anticoagulation treatment. Indeed, Figure 3 shows that the INR for those patients
consistently falls outside the desired target range, between 2 and 3. The patterns observed
in Figure 3 are consistent across most patients.
The number of clinical visits depends on the patient at hand, and ranges from a single
visit to a maximum of 29 visits. It is important to note that this maximum number of visits
is due to the fact that our data collection is limited in time, and does not span the entire
length of the patient’s treatment. There are 17 patients who visited the clinic only once. We
remove those patients from our data set since we cannot observe their INR responses to the
prescribed dosages. For each patient, we do not know the last dose taken prior to the first
recorded INR value (patients may have begun treatment earlier). Therefore, we remove all
initial INR measurements from the data. There are also some missing values in our data set.
For example, there are 10 patients with no gender listed. Additionally, there are missing
INR values for 6 patients. Finally, different conventions for warfarin dose prescriptions are
used, and some are hard to interpret. We remove all patients with missing or erroneous data,
and are left with a total of 503 patients. For each patient, we compute the average daily
warfarin dose prescribed at each visit, and use that as a covariate in our model.
5.2. Fitting to Data
We begin by investigating the validity of our normality assumption for the log-transformed
INR, as described in §3.2. In Figure 4, we present a QQ-plot for the residuals of the model
in (3.2). Figure 4 shows that the normality assumption is reasonable.
In Table 1, we present point estimates of some model parameters and statistical sig-
nificance results, at the 95% confidence level, for selected fixed effects in (3.2). The fixed
effects that were found to be significant are: the warfarin dose, adult-onset-diabetes-mellitus
(AODM), and previous cerebrovascular accident (CVA). The significance of those factors is
consistent with the physician’s intuition.
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Figure 3: Plot of the INR for three AF patients
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Figure 4: QQ-plot of residuals of the dose-
response model.
6. Estimates of POMDP Model Parameters
In this section, we estimate the parameters of the POMDP model, described in §3, based
on our data set. In §7, we numerically solve the resulting POMDP and formulate several
insights. Solving POMDPs is intractable in general, partly because the optimal policy may
be infinitely large. To alleviate some of that computational burden, we discretize as follows.
State space. As explained in §3, we define the state in our POMDP model, at a given
decision epoch t, to be the pair (INRt, γ). We fit our dose-response model in (3.2) to data, and
estimate corresponding γ values for our patient population. We find that the average value
of γ in our data set is equal to 0.08, its first quartile is equal to 0.03, and its third quartile
equal to 0.13. Based on these estimates, we designate three levels of patient sensitivity: (1)
Low (γ = 0.05), (2) Medium (γ = 0.11) and (3) High (γ = 0.15). Categorizing patients into
three levels of sensitivity is often done by physicians in practice; see Moyer et al. (2009).
We discretize INR values into 5 different intervals. These intervals are: I1 = (0, 1.5],
I2 = (1.5, 2], I3 = (2, 3], I4 = (3, 4], and I5 = [4,∞). Discretizing the INR as such is
consistent with medical practice; e.g., see Jaffer and Bragg (2003). Since we have 3 values
for γ and 5 intervals for the INR, the total number of states is 5× 3 = 15 states.
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Category Coefficient Std. error p-value
AODM (0) 0.914 0.11 < 0.001
RH (0) 0.00175 0.025 0.95
HYP (0) 0.0384 0.025 0.13
MHV (0) -0.339 0.083 < 0.001
CVA (0) -0.0696 0.027 0.011
ULC (0) -0.01323 0.027 0.062
AGE IND (0) -0.0325 0.023 0.15
Risk of fall medium (1) 0.0392 0.76 0.45
AC (0) 0.0309 0.031 0.33
Gender (Female) 0.0554 0.030 0.57
Warfarin dose – – < 0.001
Table 1: Partial results for the fixed effects and covariance parameters specified in (3.2).
Point estimates of model coefficients are shown with corresponding standard errors and p-
values of tests for statistical significance. The numbers in parentheses indicate whether or
not the effect is present (1) or not (0).
Action space. We let the set of allowed warfarin doses coincide with the available con-
centrations of warfarin pills in practice; see Ansell et al. (2001). That is, we let d (in mgs)
be one of the following: 0, 2.5, 5, 7.5, and 10. A dose d = 0 corresponds to interrupting
warfarin treatment until the next patient visit.
State-transition probabilities. For each dose d, we associate a 15 × 15 state-transition
probability matrix, MdS. We let M
d
S(s, s
′) = PS(s, d, s′) where, as explained in §3, PS(s, d, s′)
denotes the probability that the next state is s′ given that the current state is s and the
current action taken is d. Since the transition from a given state to another state with a
different patient sensitivity is not possible, MdS has a block diagonal matrix structure, where
each block corresponds to a given patient’s sensitivity level.
To compute the terms of each submatrix, we rely on the dynamics of our dose-response
model in (3.2). To illustrate, let the current dose be equal to d0 and let γ0 denote patient
sensitivity. Then, ln(INR) is normally distributed with mean β + γ0d0 and variance σ
2
 ,
independently of the current INR level. Thus, the probability of transitioning into a certain
INR interval can be computed based on the cumulative distribution function of a normal
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random variable. For example, the probability of transitioning into the interval (1.5, 2] is
given by Φ((ln(2)− β − γ0d0)/σ)−Φ((ln(1.5)− β − γ0d0)/σ) where Φ(·) is the cumulative
distribution function of a (standard) normal random variable with mean 0 and variance 1.
Risk function. We use the risk function in Figure 2. In order to compute the immediate
risk r((I, γ), d) associated with transitioning into state (I, γ), given a current prescribed
dose d, we assume that the new INR coincides with the midpoint of I. For example, the
immediate risk associated with an INR transition into the interval (2, 3) is r(2.5) = 0. We
let r(5) be the immediate risk associated with a transition into the interval [4,∞).
We let the time horizon T be long enough to allow convergence to a desired belief about
patient sensitivity. The belief about patient sensitivity, in our discrete context, is a proba-
bility vector (pL, pM , pH) of probabilities that γ is low, medium, or high, respectively. This
probability vector is updated sequentially according to a simple application of Bayes’ rule,
given the observed INR values. The convergence criterion for our belief updating procedure
is the final desired belief probability that γ is either low, medium, or high; we denote this
convergence probability by p. In §7, we vary the desired belief and find that an upper bound
T = 200 guarantees convergence in each case. We let the discount factor θ = 0.8.
Recognizing that θ = 0.8 may be considered low in a clinical setting, we also conducted
some of the experiments with a discount factor of 0.98. The results that we obtain are largely
consistent. For the MDP, we proved that the myopic policy is optimal, so the discount factor
has no effect at all. In the POMDP, we show, numerically, next that the myopic policy is
roughly optimal, so that there is also little impact for the discount factor.
7. Numerical Study
In this section, we present numerical results corresponding to both the initiation and main-
tenance stages of treatment. For the numerical solution of the POMDP model, we rely on
the widely used “pomdp-solve” software; see Cassandra (2014). Based on our results, we
derive insights pertaining to the design of anticoagulation therapy in practice. We present
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additional numerical results and discuss related insights in the supplement.
7.1. The Initiation Stage
Near optimality of the myopic policy. We use simulation to compare the performances
of the optimal solution for the POMDP and the myopically optimal solution. (We include
detailed numerical results and a description of our simulation experiments in §S4.1 of the
supplement.) We consider low, medium, and high sensitivity patients, alternative values for
p (0.7, 0.9, and 0.995), and different initial belief probability vectors. For each sensitivity
level and each value of p, we report estimates of the average TTR, average risk value, and
average number of visits required in the initiation stage to reach convergence.
Our results indicate that the performance of the myopically optimal policy is close to that
of the POMDP optimal policy, given our discretization of the problem which is consistent
with medical practice. Indeed, for all initial belief vectors and all patient sensitivities con-
sidered, the average TTR and risk values are close under those two policies. Thus, our study
gives numerical support to solving the single-stage problem instead of the POMDP; this is
practically useful given the numerical complexity of the POMDP.
Length of the initiation stage. In Figures 5, 6, and 7, we report simulation estimates
of the average risk as a function of the number of visits in the initiation stage, averaged
over 10,000 independent simulation replications (we deliberately choose such a large number
of replications to smoothe out the stochastic noise in the plots). In Figure 5, we consider
a uniform initial belief vector and a medium sensitivity level. In Figure 6, we consider a
uniform initial belief vector and a high sensitivity level. Finally, in Figure 7, we consider a
high sensitivity level and an initial probability vector which assigns a probability equal to
0.6 to high sensitivity, and 0.2 to both medium or low sensitivities.
Figures 5, 6, and 7 show that even though smaller risk values are obtained for high values
of p, as expected, the risks corresponding to smaller values of p need not be much larger.
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Therefore, a relatively small number of visits for the initiation stage may be sufficient in
practice. For example, Figures 5 and 6 show that the greatest reduction in risk results from
the initial 20 visits to the clinic. Beyond 20 visits (corresponding to p = 0.54 in Figure 5
and p = 0.68 in Figure 6), risk reduction is relatively marginal.
Such lengths for the initiation stage are reasonable particularly in light of recent tech-
nological advances which permit INR self-monitoring by patients. Indeed, self-monitoring
reduces the number of required patient visits to the clinic, enables more frequent testing,
and is recommended by both The National Institute for Health and Care Excellence (2014)
and The United States Department of Health and Human Services (2014).
Effect of patient sensitivity on learning. Comparing Figures 5 and 6 shows that, for
the same initial probability vector, it usually takes longer to learn about a medium sensitivity,
compared to a high sensitivity (and to a low sensitivity). Indeed, in both figures we consider
a uniform initial probability vector, but different sensitivity values (medium in Figure 5 and
high in Figure 6). However, reaching p = 0.4 for a medium γ, i.e., in Figure 5, requires
around 15 visits, whereas it can be reached in around 5 visits for high γ, i.e., in Figure 6.
The intuition behind this observation is that patients with either low or high sensitivities are
easier to identify due to their more extreme reactions to prescribed dosages. Also, Figures
5, 6, and 7 clearly show that the required number of patient visits sharply increases as our
desired final belief probability about γ increases.
Effect of the initial belief vector. Comparing Figures 6 and 7 quantifies the advantage
of selecting an adequate initial belief vector. Indeed, those figures assume the same (high)
sensitivity but different initial belief vectors. Figure 7 shows that a high level of confidence,
p = 0.8, is reached in less than 10 visits with a strong initial belief about a high sensitivity
value. In contrast, a level of confidence p = 0.65 is reached after about 20 visits in Figure
6. Our recommendation to physicians is to allocate a significant effort in pre-diagnosing the
patient, e.g., via preliminary medical tests or by soliciting additional patient information, to
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Figure 6: Optimal average risk for a uniform
initial belief vector and a high γ.
identify unique patient profiles and form a better initial belief about patient sensitivity; this
would lead to substantially reducing the length of the initiation stage.
7.2. The Maintenance Stage
We now turn to the maintenance stage of treatment. Our objective is to demonstrate,
numerically, the importance of effectively learning about γ during the initiation stage, and
to quantify the effect of ignoring a previous stroke on future treatment. We assume that
the physician has formed a belief about γ during the initiation stage; this belief remains
unchanged during the maintenance stage. In particular, we assume that the belief about
γ at the beginning of the maintenance stage is normally distributed with mean µM and
variance σ2M . In this section, we plot and discuss corresponding figures; we include detailed
numerical results in §S4.2 of the supplement.
Correct assessment of patient sensitivity. In Figure 8, we consider a medium sensitiv-
ity γtrue = 0.11, and assume that µM = γtrue = 0.11. We then vary the squared coefficient of
variation (SCV) of the belief about γ, SCV ≡ σ2M/µ2M , and study the effect of this variation
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on the optimal risk in the maintenance stage (corresponding to the myopically optimal dose).
Figure 8 shows that the optimal risk in the maintenance stage increases as the uncertainty
about γ increases. In Figure 9, we assume that σ2M = 0 and, once more, a medium sensitivity
γtrue = 0.11. We vary the value of µM and find, as expected, that the lowest value of the
optimal risk is achieved at µM = γtrue = 0.11 (mean equal to true value). Interestingly,
having µM = γtrue may not always be risk minimizing, as we show next.
In Figure 10, we assume that the physician’s belief about γ is uncertain. In particular,
we assume that γtrue = 0.11 but σ
2
M = 5. Figure 10 shows that with such a high σ
2
M
value, the optimal risk does not, surprisingly, correspond to µM = γtrue = 0.11. Indeed,
the optimal risk is monotone increasing in µM , so that underestimating sensitivity results
in a smaller risk value. In other words, we can formulate the following recommendation: If
the physician remains highly uncertain about the true value of γ after the initiation stage
(e.g., in exceptional cases where the patient state is unusually variable), then it may be risk
minimizing to underestimate γ.
Effect of ignoring previous stroke events. We now study the effect of ignoring a
previous stroke when treating a patient in the maintenance stage. For this, we assume a
sensitivity level γ = 0.12 and compare the following three scenarios for different values of the
SCV and of µM : (1) the patient does not experience any previous strokes; (2) the patient
experiences a stroke and the physician updates the fixed effect β in (3.2) accordingly after
this stroke; and (3) the patient experiences a stroke and the physician does not update β.
We present our results in Table 2. Table 2 shows that risk can considerably increase by
not taking into account the occurrence of a previous stroke event, and that this increase is
particularly strong when the uncertainty, σ2M , about γ is low. This is intuitively clear since
in this case the physician is “confident” about a wrong model for the patient’s INR. For
example, for an SCV equal to 0.01 and µM = 0.02, the optimal risk increases from 5.1 to
14.1 when ignoring a previous stroke in designing future treatment.
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XXXXXXXXXXXXSCV for γ
µM 0.02 0.04 0.08 0.1 0.12
No previous stroke
0.01 11.9 (12.7) 2.06 (6.4) 1.39 (3.2) 1.37 (2.5) 1.37 (2.1)
0.5 3.22 (8.2) 1.48 (4.1) 1.36 (2.1) 1.37 (1.6) 1.38 (1.4)
5 1.37 (2.6) 1.38 (1.3) 1.41 (0.64) 1.41 (0.52) 1.42 (0.43)
Previous stroke taken into account
0.01 5.13 (9.3) 1.69 (4.7) 1.38 (2.3) 1.36 (1.9) 1.36 (1.5)
0.5 2.19 (6.0) 1.42 (3.0) 1.36 (1.5) 1.37 (1.2) 1.37 (1.0)
5 1.36 (1.8) 1.37 (0.90) 1.39 (0.45) 1.39 (0.36) 1.40 (0.30)
Previous stroke ignored i.e., use same dosages as without a stroke
0.01 14.1 2.34 1.44 1.39 1.37
0.5 3.77 1.57 1.37 1.36 1.36
5 1.39 1.36 1.38 1.39 1.39
Table 2: Expected risk values in the maintenance stage under different scenarios and γ =
0.12. We include in parentheses the optimal dosages required to minimize the risk criterion.
8. Concluding Remarks
In this paper, we proposed an individualized design for the anticoagulation treatment of
patients with AF. This heart condition puts patients at an increased risk of occurrence of a
stroke. Patients with AF are typically prescribed warfarin, a popular anticoagulant drug, as
a preventive measure. Despite its popularity, warfarin is notoriously difficult to manage.
We modelled the initiation stage of treatment using a POMDP model (§3). In the
POMDP modelling framework, we proposed a systematic way to learn about patient sensi-
tivity, γ, which strongly influences patient response to warfarin and is typically unobservable.
We modelled the maintenance stage of treatment using an MDP model (§4). In the
MDP modelling framework, we assumed some pre-formed belief about γ and derived several
analytical results. We analyzed data provided by a hematology clinic in Montreal (§5).
Through direct analysis and numerical experiments, we investigated issues faced by doctors in
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practice. For the initiation stage of treatment, we derived a closed-form expression for belief
updates in the POMDP framework (§3.3). We showed that the complexity of the POMDP
lies in balancing risk minimization with faster learning about γ, at each decision epoch. In
§6, we fit our POMDP model to data. In §7, we discretized our problem, consistently with
medical practice, and presented simulation results based on the numerical solution of the
POMDP. Our experiments showed that the performance of the myopically optimal policy is
close, in terms of both average risk and TTR, to the optimal POMDP policy.
We proved that the myopic policy is optimal for the MDP model (§4.2). This shows
that it suffices to solve the myopic problem, at every decision epoch, during the maintenance
stage. Moreover, there is a unique optimal dose for all decision epochs during that stage.
This is consistent with medical practice where such a dose is called the stable dose.
We formulated sufficient conditions for the existence and uniqueness of that stable, risk-
minimizing, dose for the MDP model (§4.3). We also analyzed how that dose affects other
clinical measures commonly used in medical practice, such as the TTR (§4.4). We showed
that doses which are optimal under the TTR maximization criterion may be very different
from doses which are optimal under the risk minimization criterion. This is insightful since
those two criteria are often assumed to be equivalent in medical practice.
Numerically, we investigated the required length of the initiation stage, and showed
that the greatest decrease in risk typically results from the initial visits to the clinic. This
substantiates that it suffices to have a short initiation stage in practice. We also studied how
that length is affected by the physician’s initial belief about patient sensitivity. Consistent
with intuition, we found that the length of the initiation stage increases sharply as the desired
level of accuracy about γ increases. We also found that the initial belief about γ strongly
impacts the required length for the initiation stage.
At the onset of the maintenance stage, the physician has already formed a reliable belief
about patient sensitivity. We showed the importance of forming a correct belief about γ at
the beginning of the maintenance stage, and showed that if the physician is uncertain about
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the value of patient sensitivity, then it may be best to underestimate it. We also studied the
effect of ignoring a previous stroke on subsequent dosing decisions and risks.
In both our POMDP and MDP frameworks, we took the physician’s perspective and
excluded costs that patients may incur upon each visit to the clinic. A natural extension of
our models would be to include both visiting costs and the effect of time between successive
visits. Then, the decision to be made at each epoch concerns both the dosage and the
time until the next visit. It would be interesting to investigate structural properties of the
solutions of our decision-making problems in that case.
In this paper, we assumed that patients take their doses as prescribed, since we did
not have any additional information about how patients manage their prescriptions. It is
important to try to gather such data in the future, in order to develop more reliable models.
Finally, there is a need to conduct a randomized trial to test the effectiveness of our proposed
treatment procedure, and to compare it to treatments that are currently used in practice.
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